Revolution Medicines officer sells 2,010 RVMD shares

Revolution Medicines, Inc. officer Wang Xiaolin reported an open-market sale of 2,010 shares of common stock on March 17, 2026 at an average price of $99.4804 per share.

Rhea-AI Filing Summary

Revolution Medicines, Inc. officer Wang Xiaolin reported an open-market sale of 2,010 shares of common stock on March 17, 2026 at an average price of $99.4804 per share. The transaction was executed under a pre-arranged Rule 10b5-1 instruction letter to cover tax withholding on vested RSUs. Following the sale, Wang holds 116,063 shares directly, including 48,700 restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 2,010 shares

Net Sell 1 txn

Insider Wang Xiaolin

Role See Remarks

Sold 2,010 shs ($200K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,010	$99.4804	$200K

Holdings After Transaction: Common Stock — 116,063 shares (Direct)

Footnotes (2)

1. F1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on November 17, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after December 15, 2025.
2. F2. Includes 48,700 RSUs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Wang Xiaolin report for Revolution Medicines (RVMD)?

Wang Xiaolin reported selling 2,010 shares of Revolution Medicines common stock in an open-market transaction. The shares were sold on March 17, 2026 at an average price of $99.4804 per share, as disclosed in a Form 4 insider trading report.

Why was the latest RVMD insider sale by Wang Xiaolin executed under a Rule 10b5-1 plan?

The sale was executed under a Rule 10b5-1 instruction letter adopted on November 17, 2025. According to the disclosure, the primary purpose was to satisfy Wang Xiaolin’s tax withholding obligations arising from the vesting of restricted stock units after December 15, 2025.

How many Revolution Medicines (RVMD) shares does Wang Xiaolin hold after this transaction?

After the reported sale, Wang Xiaolin holds 116,063 shares of Revolution Medicines common stock directly. This total includes 48,700 restricted stock units, which represent share awards that typically vest over time according to the company’s equity compensation arrangements.

What was the sale price for the 2,010 RVMD shares sold by Wang Xiaolin?

The 2,010 Revolution Medicines shares were sold at an average price of $99.4804 per share. This average price reflects the execution prices for the open-market transaction disclosed in the Form 4 insider trading report filed for Wang Xiaolin.

Does the tax-related nature of Wang Xiaolin’s RVMD share sale affect its interpretation?

Yes. The sale was specifically described as satisfying tax withholding obligations upon RSU vesting, under a pre-arranged Rule 10b5-1 instruction letter. Such transactions are typically viewed as routine, compensation-related events rather than discretionary market-timing sales by the insider.

What are the RSUs mentioned in Wang Xiaolin’s Revolution Medicines (RVMD) holdings?

The filing notes that Wang Xiaolin’s post-transaction holdings include 48,700 restricted stock units, or RSUs. RSUs are equity awards that convert into common shares upon vesting, usually subject to continued employment and other conditions set by the company’s compensation plans.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/19/2026 - 06:53 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wang Xiaolin

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		2,010	D	$99.4804	116,063(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on November 17, 2025 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after December 15, 2025.

2. Includes 48,700 RSUs.

Remarks:

EVP, Clinical Development

	/s/ Jack Anders, as Attorney-in-fact for Xiaolin Wang	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)